CA3218011A1 - Un inhibiteur de xanthine oxydase - Google Patents

Un inhibiteur de xanthine oxydase Download PDF

Info

Publication number
CA3218011A1
CA3218011A1 CA3218011A CA3218011A CA3218011A1 CA 3218011 A1 CA3218011 A1 CA 3218011A1 CA 3218011 A CA3218011 A CA 3218011A CA 3218011 A CA3218011 A CA 3218011A CA 3218011 A1 CA3218011 A1 CA 3218011A1
Authority
CA
Canada
Prior art keywords
alkyl
substituted
compound
group
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3218011A
Other languages
English (en)
Inventor
Dongfang Shi
Changjin FU
Yan Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Atom Bioscience and Pharmaceutical Co Ltd
Original Assignee
Jiangsu Atom Bioscience and Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Atom Bioscience and Pharmaceutical Co Ltd filed Critical Jiangsu Atom Bioscience and Pharmaceutical Co Ltd
Publication of CA3218011A1 publication Critical patent/CA3218011A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne une classe d'inhibiteurs de xanthine oxydase, qui sont des composés représentés par la formule générale (I) ou des sels pharmaceutiquement acceptables de ceux-ci. Les inhibiteurs de xanthine oxydase ont une excellente activité inhibitrice de la xanthine oxydase et ont une valeur d'application potentielle dans des médicaments anti-goutte, des médicaments anti-hyperuricémie, etc.
CA3218011A 2021-04-29 2022-04-28 Un inhibiteur de xanthine oxydase Pending CA3218011A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110493446 2021-04-29
CN202110493446.2 2021-05-07
PCT/CN2022/089979 WO2022233264A1 (fr) 2021-04-29 2022-04-28 Classe d'inhibiteurs de xanthine oxydase

Publications (1)

Publication Number Publication Date
CA3218011A1 true CA3218011A1 (fr) 2022-11-10

Family

ID=83483098

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3218011A Pending CA3218011A1 (fr) 2021-04-29 2022-04-28 Un inhibiteur de xanthine oxydase

Country Status (9)

Country Link
EP (1) EP4335844A1 (fr)
JP (1) JP2024516040A (fr)
KR (1) KR20240005050A (fr)
CN (1) CN115160299A (fr)
AU (1) AU2022270242A1 (fr)
BR (1) BR112023022484A2 (fr)
CA (1) CA3218011A1 (fr)
MX (1) MX2023012844A (fr)
WO (1) WO2022233264A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116715633A (zh) * 2022-04-27 2023-09-08 江苏新元素医药科技有限公司 可用于降尿酸的化合物
TW202342455A (zh) * 2022-04-27 2023-11-01 大陸商江蘇新元素醫藥科技有限公司 可用於痛風的化合物
CN116283946B (zh) * 2023-03-27 2024-05-07 武汉工程大学 5-(n-取代吲哚-5-基)异噁唑-3-甲酸衍生物及其合成方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010044404A1 (fr) * 2008-10-15 2010-04-22 キッセイ薬品工業株式会社 Derive heterocyclique fusionne et son utilisation a des fins medicales
KR20100092909A (ko) * 2009-02-13 2010-08-23 주식회사 엘지생명과학 잔틴 옥시다제 저해제로서 효과적인 신규 화합물, 그 제조방법 및 그를 함유하는 약제학적 조성물
TWI423962B (zh) * 2009-10-07 2014-01-21 Lg Life Sciences Ltd 有效作為黃嘌呤氧化酶抑制劑之新穎化合物、其製備方法及含該化合物之醫藥組成物
TWI548630B (zh) * 2011-04-06 2016-09-11 Ｌｇ生命科學有限公司 １－（３－氰基－１－異丙基－吲哚－５－基）吡唑－４－羧酸結晶型及其製造方法
CN103980267B (zh) * 2013-02-08 2018-02-06 镇江新元素医药科技有限公司 一类新型黄嘌呤氧化酶抑制剂的化合物及其药物组合物

Also Published As

Publication number Publication date
EP4335844A1 (fr) 2024-03-13
BR112023022484A2 (pt) 2024-01-09
CN115160299A (zh) 2022-10-11
AU2022270242A1 (en) 2023-12-21
TW202246238A (zh) 2022-12-01
MX2023012844A (es) 2023-12-06
JP2024516040A (ja) 2024-04-11
WO2022233264A1 (fr) 2022-11-10
KR20240005050A (ko) 2024-01-11

Similar Documents

Publication Publication Date Title
CA3218011A1 (fr) Un inhibiteur de xanthine oxydase
EP1490365B1 (fr) Azaindoles en tant qu'inhibiteurs de kinases a terminaison c-jun n
EP1490364B1 (fr) 7-azaindoles en tant qu'inhibiteurs de kinases a terminaison c-jun n pour le traitement de troubles neurodegeneratifs
ES2878973T3 (es) Derivado de fenilo de imidazopiridinamina y uso del mismo
CA2923269C (fr) Derive d'acide cycloalkylique, procede de preparation et utilisation pharmaceutique de celui-ci
UA109660C2 (xx) Заміщені 5-фтор-1h-піразолопіридини та їх застосування
RU2677698C1 (ru) Производные триазолопиридазина в качестве модуляторов активности tnf
BR112016011844B1 (pt) Derivados de triazolpiridina como moduladores de atividade de tnf
CN111592528A (zh) 氘代的哒嗪酮及其衍生物和药物组合物
US20140194458A1 (en) Derivate, preparation method and use of 10-methoxycamptothecine
WO2010010935A1 (fr) Dérivé de n-arylacétamide d’hétérocyclidène optiquement actif
TW202227424A (zh) 芳基或雜芳基取代５員芳雜環化合物及其用途
US6518294B2 (en) Fused pyrazolyl compounds
CA3158731A1 (fr) Composes antagonistes du recepteur de l'adenosine
JPH03505204A (ja) ３環式３―オキソ―プロパンニトリル誘導体およびその調製方法
CA2819822C (fr) Composes d'oxazolo [5,4-b] pyridin-5-yle et leur utilisation pour le traitement du cancer
WO2018066646A1 (fr) Dérivé de l'urée
US8030303B2 (en) Salt of morpholine compound
TWI844849B (zh) 一類黃嘌呤氧化酶抑制劑
EP1420023B1 (fr) Utilisation de composés de pyrazole condensé pour la préparation médicaments destinés au traitement de l'hypertension
CN111592558B (zh) 具有尿酸再吸收抑制作用的杂环化合物
JP7082107B2 (ja) アミド誘導体
CN116715633A (zh) 可用于降尿酸的化合物
WO2021249468A1 (fr) Procédé de préparation d'un composé chloré
JP5975122B2 (ja) ［（４−ヒドロキシ−２−オキソ−１，２，５，６−テトラヒドロ−３−ピリジニル）カルボニル］グリシン化合物の結晶形及びそれらの製造方法

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20231026

EEER Examination request

Effective date: 20231026

EEER Examination request

Effective date: 20231026

EEER Examination request

Effective date: 20231026